Table 3.
HRs and 95% CIs for ESRD per 10-pg/ml FGF-23 increment according to category of baseline kidney function in the ARIC study (1990–2010; n=13,448)
| eGFR Model (ml/min per 1.73 m2)a | Participants (n) | HR (95% CI) | P Value | P Value for Interactionb |
|---|---|---|---|---|
| eGFRCr≥90 | ||||
| Model 1 | 9779 | 1.09 (1.04 to 1.15) | <0.001 | — |
| Model 5 | 1.11 (1.01 to 1.22) | 0.03 | — | |
| eGFRCr 60–89 | 3404 | |||
| Model 1 | 1.18 (1.07 to 1.30) | 0.001 | 0.78 | |
| Model 5 | 1.07 (0.95 to 1.21) | 0.25 | 0.56 | |
| eGFRCr<60 | 265 | |||
| Model 1 | 1.10 (1.07 to 1.13) | <0.001 | 0.60 | |
| Model 5 | 1.11 (1.01 to 1.23) | 0.03 | 0.21 |
a
Models are as follows: model 1 is unadjusted (no covariates included in the model); and model 5 is adjusted for age, sex, race, diabetes, systolic BP, antihypertensive medication, eGFRCr, eGFRCys, eGFRCr-Cys, HDL cholesterol, body mass index, C-reactive protein, β2-microglobulin, phosphate, calcium, and parathyroid hormone.
b
Interaction of GFR category using eGFRCr≥90 ml/min per 1.73 m2 as the reference group (all P>0.20). Dash represents reference group for test of interaction.